The Institute for Clinical and Economic Review (ICER) announced plans to review FKD Therapies Oy and Ferring Pharmaceuticals’ Instiladrin for the treatment of bladder cancer.
According to a press release, the Food and Drug Administration (FDA) is expected to make a decision on the drug later this year.
ICER is accepting input for the development of an evidence report until 5 p.m. EST March 10.
To see the timeline of this review, click here.
Click here to read the full press release.